Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Neurourol Urodyn. 2019 Oct 3;39(1):108–115. doi: 10.1002/nau.24170

FIGURE 3.

FIGURE 3

mRNA levels of TRPV1, TNF-α, and iNOS of L6 DRG. In SCI mice, TRPV1, TNF-α, and iNOS levels were higher than those of SI mice with CSF treatment. After p38 MAPKi treatment, TRPV1, TNF-α, and iNOS levels in SCI mice were lower than those of SCI mice with CSF treatment. Data are shown as relative values of mRNA expression in SCI mice vs SI mice whereas the statistical analysis was performed using the mRNA expression ratio against the house keeping gene (β-actin) calculated in each mouse. *P < .05 vs SI+CSF mice. †P < .05 vs SCI + CSF mice. CSF, cerebrospinal fluid; DRG, dorsal root ganglia; iNOS, inducible nitric oxide synthase; mRNA, messenger RNA; p38 MAPKi, p38 MAPK inhibitor; SI, spinal intact; SCI, spinal cord injury; TNF-α, tumor necrosis factor-α; TRPV1, transient receptor potential cation channel subfamily V member 1